You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
MicroRNAs in fibrosis: opportunities and challenges
|
|---|---|
| Published in |
Arthritis Research & Therapy, January 2016
|
| DOI | 10.1186/s13075-016-0929-x |
| Pubmed ID | |
| Authors |
Steven O’Reilly |
| Abstract |
MicroRNAs (miRNAs) are small, non-coding RNAs that mediate mRNA cleavage, translational repression or mRNA destabilisation and are around 22-25 nucleotides in length via partial complementary binding to the 3' untranslated region in target transcripts. They are master regulators of gene expression. Fibrosis is an important cause of morbidity and mortality in the world, and there are currently no accepted treatments for fibrosis. Many novel miRNAs are now associated with fibrosis, both organ-specific and systemic, as in the prototypical fibrotic disease systemic sclerosis. Recently, the targets of these altered miRNAs have been validated and defined new biochemical pathways. Dysregulated miRNAs are amenable to therapeutic modulation. This review will examine the role of miRNAs in fibrosis and the opportunities and challenges of targeting them. |
X Demographics
The data shown below were collected from the profiles of 4 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Singapore | 1 | 25% |
| Unknown | 3 | 75% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 4 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 119 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| South Africa | 1 | <1% |
| Unknown | 118 | 99% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 20 | 17% |
| Researcher | 15 | 13% |
| Student > Ph. D. Student | 11 | 9% |
| Student > Doctoral Student | 9 | 8% |
| Student > Master | 8 | 7% |
| Other | 16 | 13% |
| Unknown | 40 | 34% |
| Readers by discipline | Count | As % |
|---|---|---|
| Biochemistry, Genetics and Molecular Biology | 22 | 18% |
| Medicine and Dentistry | 20 | 17% |
| Agricultural and Biological Sciences | 10 | 8% |
| Immunology and Microbiology | 7 | 6% |
| Pharmacology, Toxicology and Pharmaceutical Science | 2 | 2% |
| Other | 9 | 8% |
| Unknown | 49 | 41% |
Attention Score in Context
This research output has an Altmetric Attention Score of 15. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 09 August 2018.
All research outputs
#2,470,142
of 25,374,917 outputs
Outputs from Arthritis Research & Therapy
#454
of 3,380 outputs
Outputs of similar age
#41,023
of 402,001 outputs
Outputs of similar age from Arthritis Research & Therapy
#17
of 88 outputs
Altmetric has tracked 25,374,917 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 90th percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 3,380 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 9.2. This one has done well, scoring higher than 86% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 402,001 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 89% of its contemporaries.
We're also able to compare this research output to 88 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 80% of its contemporaries.